Trials / Completed
CompletedNCT00330850
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 650 (planned)
- Sponsor
- ProEthic Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura. The study is also intended to show the effectiveness of PRO-513 for associated symptoms of nausea, photophobia, and phonophobia due to a migraine attack.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRO-513 |
Timeline
- Start date
- 2006-05-01
- Completion
- 2006-12-01
- First posted
- 2006-05-29
- Last updated
- 2007-04-02
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00330850. Inclusion in this directory is not an endorsement.